Compare Crispr Therapeutics AG (CRSP) vs Toyota Motor Corp (TM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Toyota Motor Corp — how do they compare? Crispr Therapeutics AG trades at $50.76 (market cap $4.97B), while Toyota Motor Corp trades at $176.77 (market cap $205.39B). The key difference: Toyota Motor Corp is far larger — about 41.3× Crispr Therapeutics AG's market cap, and Toyota Motor Corp pays a 3.59% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | TM | |
|---|---|---|
Market Cap | $4.97B | $205.39B |
Sector | Health | Consumer Cyclical |
52-Week High | $76.78 | $248.29 |
52-Week Low | $44.34 | $166.50 |
Enterprise Value | $3.32B | $369.58B |
Dividend Yield | — | 3.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
Toyota Motor trades at $174.75, down 0.96% with neutral technical signals. The stock shows attractive valuation metrics including a P/E of 9.58 and P/B of 0.84, trading below industry averages. Recent earnings have consistently beaten expectations, with Q1 2026 EPS of $4.00 exceeding the $3.11 estimate. The company's $3.6 billion Texas expansion signals strong growth commitment amid positive hybrid vehicle sales momentum.
Toyota presents a compelling value opportunity with strong fundamentals and consistent earnings performance. However, declining profit margins and increasing debt levels warrant monitoring. Analyst consensus leans neutral with 62.5% hold ratings, suggesting cautious optimism about the company's strategic investments and hybrid leadership position in the evolving automotive landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Toyota Motor Corp
Founded in 1937, Toyota is one of the world's largest automakers with 10.38 million units sold at retail in fiscal 2022 across its light vehicle brands. Brands include Toyota, Lexus, Daihatsu, and truck maker Hino.
Read more on TM →
